149 related articles for article (PubMed ID: 38287608)
21. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
[TBL] [Abstract][Full Text] [Related]
22. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
Curtis JR; McInnes IB; Rahman P; Gladman DD; Peterson S; Agarwal P; Yang F; Kollmeier AP; Hsia EC; Shiff NJ; Zhou B; Han C; Shawi M; Tillett W; Mease PJ
Adv Ther; 2022 Oct; 39(10):4613-4631. PubMed ID: 35947349
[TBL] [Abstract][Full Text] [Related]
24. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
[TBL] [Abstract][Full Text] [Related]
25. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
Kavanaugh A; Baraliakos X; Gao S; Chen W; Sweet K; Chakravarty SD; Song Q; Shawi M; Rahman P
Adv Ther; 2023 May; 40(5):2439-2456. PubMed ID: 36995469
[TBL] [Abstract][Full Text] [Related]
26. Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.
Orbai AM; Coates LC; Deodhar A; Helliwell PS; Ritchlin CT; Leibowitz E; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Jiang Y; Liu Y; Han C
Patient; 2022 Nov; 15(6):657-668. PubMed ID: 35768650
[TBL] [Abstract][Full Text] [Related]
27. Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
McGonagle D; McInnes IB; Deodhar A; Schett G; Shawi M; Kafka S; Karyekar CS; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Ritchlin CT; Rahman P; Mease PJ
Rheumatology (Oxford); 2021 Nov; 60(11):5337-5350. PubMed ID: 33822898
[TBL] [Abstract][Full Text] [Related]
28. Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study.
Coates LC; Rahman P; Mease PJ; Shawi M; Rampakakis E; Kollmeier AP; Xu XL; Chakravarty SD; McInnes IB; Tam LS
BMC Rheumatol; 2024 Feb; 8(1):6. PubMed ID: 38310261
[TBL] [Abstract][Full Text] [Related]
29. Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
Ritchlin CT; Deodhar A; Boehncke WH; Soriano ER; Kollmeier AP; Xu XL; Zazzetti F; Shawi M; Jiang Y; Sheng S; Helliwell PS
ACR Open Rheumatol; 2023 Mar; 5(3):149-164. PubMed ID: 36762512
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
Haroon M; Ahmad M; Baig MN; Mason O; Rice J; FitzGerald O
Arthritis Res Ther; 2018 Apr; 20(1):73. PubMed ID: 29665824
[TBL] [Abstract][Full Text] [Related]
31. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
[TBL] [Abstract][Full Text] [Related]
32. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
[TBL] [Abstract][Full Text] [Related]
33. Profile of HLA-B27-positive enthesitis/spondylitis-related arthritis in Senegal, West Africa.
Sabounji MM; Ndiaye A; Diallo S
Pediatr Rheumatol Online J; 2024 Feb; 22(1):31. PubMed ID: 38424655
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
[TBL] [Abstract][Full Text] [Related]
35. Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.
McGonagle D; McInnes IB; Deodhar A; Schett G; Shawi M; Chakravarty SD; Kollmeier AP; Xu XL; Sheng S; Xu S; Ritchlin CT; Rahman P; Mease PJ
ACR Open Rheumatol; 2023 Apr; 5(4):227-240. PubMed ID: 36880890
[TBL] [Abstract][Full Text] [Related]
36. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
Mease PJ; Gottlieb AB; Ogdie A; McInnes IB; Chakravarty SD; Rampakakis E; Kollmeier A; Xu XL; Shawi M; Lavie F; Kishimoto M; Rahman P
Clin Rheumatol; 2024 Jan; 43(1):241-249. PubMed ID: 37787903
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
[TBL] [Abstract][Full Text] [Related]
38. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
Marzo-Ortega H; Sieper J; Kivitz AJ; Blanco R; Cohen M; Pavelka K; Delicha EM; Stefanska A; Richards HB; Rohrer S
Lancet Rheumatol; 2020 Jun; 2(6):e339-e346. PubMed ID: 38273597
[TBL] [Abstract][Full Text] [Related]
39. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Ritchlin CT; Helliwell PS; Boehncke WH; Soriano ER; Hsia EC; Kollmeier AP; Chakravarty SD; Zazzetti F; Subramanian RA; Xu XL; Zuraw QC; Sheng S; Jiang Y; Agarwal P; Zhou B; Zhuang Y; Shawi M; Karyekar CS; Deodhar A
RMD Open; 2021 Feb; 7(1):. PubMed ID: 33568556
[TBL] [Abstract][Full Text] [Related]
40. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
Barkham N; Keen HI; Coates LC; O'Connor P; Hensor E; Fraser AD; Cawkwell LS; Bennett A; McGonagle D; Emery P
Arthritis Rheum; 2009 Apr; 60(4):946-54. PubMed ID: 19333933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
